Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: Larry Liebman who wrote (8)	11/30/1999 1:53:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 598

Seems like an unusually high # of shares to be outstanding in a small cap biotech IPO, i.e., 41 million+. Yeah, a fact of life after starting out with the big slug of private money and some stars. This is a slow ramp, heavy dilution plan. The hope is that leverage can be retained, and that the slow ramp will turn into a "sky". Rick...Thoughts on adding shares of ARIA at $1 1/2 ? Looks like you get 8 for 1 TLRK. Since the regulatory hurdles are enourmous, so I'm going to wait and watch. The MC:book is now so damn low -- it's really tempting. Still concerned about the separate toxicity testing for the dimerizer, however. I really want to see the technnology work, but I'm not certain that any pharmas do. I'm not implying that I'm interested in Tularik as an investment, relatively speaking. I am, however, interested in seeing them under the "public company" magnifying glass, where I can more readilly evaluate their competitive status.